ResearcherUniversity of LeicesterNo recent work listed
Franscois Runau
Matched on ORCID iD 0000-0001-6778-459X; OpenAlex author ID A5014286033. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2020: 2 papers · 2021: 2 papers
Papers 4
- Proteomic Characterization of Circulating Molecular Perturbations Associated With Pancreatic Adenocarcinoma Following Intravenous ω-3 Fatty Acid and Gemcitabin… Co-author DOI 10.1002/jpen.1952↗
- Molecular advances in pancreatic cancer: A genomic, proteomic and metabolomic approach. Last author DOI 10.3748/wjg.v27.i31.5171↗
- Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intrave… Co-author DOI 10.21037/atm.2020.02.02↗
- Endothelial Progenitor Cells are Increased in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine and Intravenous Omega 3 Compared with Controls Co-author DOI 10.21203/rs.3.rs-36878/v1↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ali Raza Arshad · 3 shared papers, 2020–2021 · strength 0.35
- Paper Proteomic Characterization of Circulating Molecular Perturbations Associated With Pancreatic Adenocarcinoma Following I… DOI 10.1002/jpen.1952↗
- Paper Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic can… DOI 10.21037/atm.2020.02.02↗
- Paper Endothelial Progenitor Cells are Increased in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine and Int… DOI 10.21203/rs.3.rs-36878/v1↗
- John Isherwood · 3 shared papers, 2020–2021 · strength 0.35
- Paper Proteomic Characterization of Circulating Molecular Perturbations Associated With Pancreatic Adenocarcinoma Following I… DOI 10.1002/jpen.1952↗
- Paper Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic can… DOI 10.21037/atm.2020.02.02↗
- Paper Endothelial Progenitor Cells are Increased in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine and Int… DOI 10.21203/rs.3.rs-36878/v1↗
- Ashley Robert Dennison · 3 shared papers, 2020–2021 · strength 0.35
- Paper Proteomic Characterization of Circulating Molecular Perturbations Associated With Pancreatic Adenocarcinoma Following I… DOI 10.1002/jpen.1952↗
- Paper Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic can… DOI 10.21037/atm.2020.02.02↗
- Paper Endothelial Progenitor Cells are Increased in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine and Int… DOI 10.21203/rs.3.rs-36878/v1↗
- Srujan Rajesh · 1 shared paper, 2021 · strength 0.22
- William P. Steward · 2 shared papers, 2020 · strength 0.20
- Paper Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic can… DOI 10.21037/atm.2020.02.02↗
- Paper Endothelial Progenitor Cells are Increased in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine and Int… DOI 10.21203/rs.3.rs-36878/v1↗
- Matthew S. Metcalfe · 2 shared papers, 2020 · strength 0.20
- Paper Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic can… DOI 10.21037/atm.2020.02.02↗
- Paper Endothelial Progenitor Cells are Increased in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine and Int… DOI 10.21203/rs.3.rs-36878/v1↗
- Wen Yuan Chung · 2 shared papers, 2020 · strength 0.20
- Paper Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic can… DOI 10.21037/atm.2020.02.02↗
- Paper Endothelial Progenitor Cells are Increased in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine and Int… DOI 10.21203/rs.3.rs-36878/v1↗
- Donald J. L. Jones · 1 shared paper, 2021 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.